# A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer

Source: https://onco.cc/trials/nct07714668/  
OnCo record `nct07714668` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Farletuzumab-exatecan, Bevacizumab, Carboplatin in ovarian cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.

## Summary

A Clinical Study of SYS6041 Combination Therapy for Recurrent Ovarian Cancer is a phase 2 interventional study registered as NCT07714668 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 171 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-04-30. Interventions recorded: SYS6041, bevacizumab, SYS6041, carboplatin, bevacizumab, paclitaxel, carboplatin, bevacizumab, SYS6041, enlonstobart, bevacizumab. Conditions listed: Ovarian Cancer, Recurrent Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07714668
- Phase: 2
- Setting: An Open-label , Multicenter, Multicohort, Phase II Clinical Study Evaluating the Efficacy and Safety of SYS6041 Combination Therapy for Recurrent Ovarian Cancer
- Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
- Enrolled: 171

## Sources

- ClinicalTrials.gov NCT07714668: https://clinicaltrials.gov/study/NCT07714668

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Farletuzumab-exatecan](https://onco.cc/drugs/farletuzumab-exatecan/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [CSPC Pharmaceutical Group](https://onco.cc/companies/cspc/)

---
JSON: https://onco.cc/api/v1/entities/nct07714668.json